Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study Davina J Hensman Moss* 1, MBBS, Antonio F. Pardiñas* 2, PhD, Prof Douglas Langbehn 3, PhD, Kitty Lo 4, PhD, Prof Blair R. Leavitt 5, MD,CM, Prof Raymund Roos 6, MD, Prof Alexandra Durr 7, MD, Prof Simon Mead 8, PhD, the REGISTRY investigators and the TRACK-HD investigators, Prof Peter Holmans 2, PhD, Prof Lesley Jones §2 , PhD, Prof Sarah J Tabrizi §1 , PhD. * These authors contributed equally to this work § These authors contributed equally to this work 1) UCL Huntington’s Disease Centre, UCL Institute of Neurology, Dept. of Neurodegenerative Disease, London, UK 2) MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK 3) University of Iowa Carver College of Medicine, Dept. of Psychiatry and Biostatistics, Iowa, USA 4) UCL Genetics Institute, Div. of Biosciences, London, UK 5) Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada 6) Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands 7) ICM and APHP Department of Genetics, Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Pitié- Salpêtrière University Hospital, Paris, France 8) MRC Prion Unit, UCL Institute of Neurology, London, UK Corresponding authors: Sarah J Tabrizi at
[email protected] Lesley Jones at
[email protected] 1 ABSTRACT Background Huntington’s disease (HD) is a fatal inherited neurodegenerative disease, caused by a CAG repeat expansion in HTT . Age at onset (AAO) has been used as a quantitative phenotype in genetic analysis looking for HD modifiers, but is hard to define and not always available.